Seelos Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares

Rhea-AI Summary

Seelos Therapeutics (Nasdaq: SEEL) announced the closure of its underwritten public offering, selling 17,530,488 shares at $2.05 per share, generating approximately $33.5 million in net proceeds. The underwriter exercised its option for an additional 2,286,585 shares. Seelos plans to allocate $3.8 million of the proceeds for the partial repayment of convertible promissory notes, with the remainder aimed at advancing its development programs and general corporate purposes. This offering was conducted under an effective 'shelf' registration statement filed with the SEC.

Positive

• Successfully raised approximately $33.5 million in net proceeds.
• Plans to utilize $3.8 million for reducing debt, potentially improving financial stability.
• Funds to further the development of its product candidates, indicating growth potential.

Negative

• Dilution risk for existing shareholders due to the public offering.
• Dependence on market conditions for future financing and product development progress.

NEW YORK, Jan. 28, 2021 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 17,530,488 shares of its common stock, at a price to the public of $2.05 per share, which includes the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares of common stock. The net proceeds to Seelos from this offering are expected to be approximately $33.5 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Seelos. Seelos intends to use an aggregate of $3.8 million of the net proceeds from the offering for the partial repayment of certain outstanding convertible promissory notes and the remainder for general corporate purposes and to advance the development of its product candidates.

BTIG, LLC acted as sole book-running manager for the offering.

The securities described above were offered by Seelos pursuant to an effective "shelf" registration statement on Form S-3 (File No. 333-251356) previously filed with the Securities and Exchange Commission (the "SEC") on December 15, 2020, amended on December 22, 2020 and declared effective by the SEC on December 23, 2020.  A final prospectus supplement and the accompanying prospectus relating to and describing the offering was filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained by visiting the SEC's website at www.sec.gov or by contacting BTIG, LLC, Attention: Equity Capital Markets, 65 East 55th Street, New York, NY 10022, by calling (212) 593-7555 or by e-mail at equitycapitalmarkets@btig.com.  

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Seelos Therapeutics:

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare disorders. The Company's robust portfolio includes several late-stage clinical assets targeting psychiatric and movement disorders, including orphan diseases.  

For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.

Forward-Looking Statements:

This press release contains forward-looking statements related to Seelos Therapeutics, Inc. and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the amount and anticipated use of proceeds from the offering and other matters that are described in Seelos' most recent periodic reports filed with the SEC, including Seelos' Annual Report on Form 10-K for the year ended December 31, 2019 filed on March 17, 2020, subsequent Quarterly Reports on Form 10-Q and the final prospectus supplement and the accompanying prospectus related to the public offering filed with the SEC on January 26, 2021, including risks and uncertainties associated with general economic and market conditions and the other risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and Seelos disclaims any intent or obligation to update these forward-looking statements except as required by law.

Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
www.seelostherapeutics.com
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-301217418.html

SOURCE Seelos Therapeutics, Inc.

FAQ

What was the size of Seelos Therapeutics' public offering?

Seelos Therapeutics completed a public offering of 17,530,488 shares.

At what price per share did Seelos sell its common stock?

The shares were sold at a price of $2.05 each.

How much net proceeds did Seelos Therapeutics expect from the offering?

Seelos expected approximately $33.5 million in net proceeds from the offering.

What will Seelos Therapeutics do with the proceeds from the offering?

The company plans to use $3.8 million for debt repayment and the remainder for general corporate purposes and product development.

What risks are associated with the public offering for Seelos shareholders?

The public offering may result in dilution for existing shareholders.